Blueprint Medicines Corporation (BPMC)

Blueprint Medicines Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	122.25	102.01	71.29	119.71	209.95	684.64
Short-Term Investments	453.99	513.47	639.36	825.28	267.17	187.21
Cash & Short-Term Investments	576.24	615.49	710.64	944.99	477.11	871.85
Cash Growth	-11.06%	-13.39%	-24.80%	98.06%	-45.28%	80.30%
Receivables	79.8	77.61	43.18	36.94	37.03	25.31
Inventory	12.95	13.61	21.22	29.7	21.82	8.58
Prepaid Expenses	33.08	35.97	33.35	35.02	18.06	22.02
Total Current Assets	702.07	742.68	808.39	1,047	554.03	927.76
Property, Plant & Equipment	97.66	100.77	115.65	115.2	120.86	101.67
Long-Term Investments	323.55	277.15	84.32	161.27	557.53	677.87
Other Long-Term Assets	72.33	59.21	40.89	26.78	19.81	11.09
Total Assets	1,196	1,180	1,049	1,350	1,252	1,718

Liabilities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Accounts Payable	0.8	6.79	4.71	2.73	8.33	4.37
Accrued Expenses	81.71	102.27	110.53	122.08	117.9	104.97
Current Portion of Long-Term Debt	111.71	105.57	69.48	34.14	-	-
Current Portion of Leases	13.74	13.35	11.93	10.58	8.09	7.94
Current Unearned Revenue	2.28	2.01	0.81	4.67	11.51	12.56
Other Current Liabilities	40.35	30.82	17.47	9.05	3.93	0.97
Total Current Liabilities	250.58	260.8	214.92	183.23	149.77	130.8
Long-Term Debt	522.66	536.58	610.96	535.28	-	-
Long-Term Leases	65.22	68.79	81.75	92.79	103.32	81.67
Long-Term Unearned Revenue	8.04	8.19	4.79	13.62	25.07	28.6
Other Long-Term Liabilities	6.97	6.79	6.21	10.3	3.34	7.24
Total Liabilities	853.47	881.15	918.64	835.23	281.49	248.31

Shareholders' Equity

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Common Stock	0.07	0.06	0.06	0.06	0.06	0.06
Additional Paid-In Capital	2,752	2,709	2,474	2,358	2,250	2,107
Retained Earnings	-2,407	-2,407	-2,340	-1,833	-1,275	-631.36
Comprehensive Income & Other	-3.24	-3.55	-3.5	-10.44	-4.13	-5.21
Total Common Equity	342.13	298.67	130.61	514.68	970.74	1,470
Shareholders' Equity	342.13	298.67	130.61	514.68	970.74	1,470
Total Liabilities & Equity	1,196	1,180	1,049	1,350	1,252	1,718

Additional Metrics

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Total Debt	713.33	724.28	774.12	672.78	111.41	89.6
Net Cash (Debt)	186.45	139.66	-6.95	405.69	923.24	1,460
Net Cash Growth	35.43%	-	-	-56.06%	-36.77%	223.03%
Net Cash Per Share	2.94	2.22	-0.11	6.80	15.78	26.00
Filing Date Shares Outstanding	64.58	63.91	61.23	59.98	59.2	57.96
Total Common Shares Outstanding	64.56	63.71	61.15	59.96	59.14	57.79
Working Capital	451.49	481.88	593.47	863.42	404.26	796.96
Book Value Per Share	5.30	4.69	2.14	8.58	16.41	25.44
Tangible Book Value	342.13	298.67	130.61	514.68	970.74	1,470
Tangible Book Value Per Share	5.30	4.69	2.14	8.58	16.41	25.44
Machinery	-	32.42	27.98	21.32	18.55	16.35
Construction In Progress	-	0.24	9.51	1.61	0.21	0.15
Leasehold Improvements	-	50.79	42.3	41.05	36.95	36.95

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jan 1, 2000

Data Sources Report a data error